Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies with attractive risk-reward profiles. Our valuation framework helps you find stocks with the right balance of growth and value characteristics for your portfolio. We provide P/E analysis, PEG ratios, and relative valuation metrics for comprehensive valuation coverage. Find value in growth with our comprehensive valuation analysis and multiples tools for growth at a reasonable price strategies.
As of 2026-04-08, Immatics N.V. Ordinary Shares (IMTX) trades at a current price of $10.32, marking a 0.68% gain in recent trading. This analysis examines key technical levels, prevailing market context, and potential short-term price scenarios for the clinical-stage biotech firm, which focuses on developing novel cancer immunotherapies. No recent earnings data is available for IMTX at the time of writing, so technical price action and sector trends offer the most visible context for market part
What do insiders think about Immatics N.V. (IMTX) Stock | Price at $10.32, Up 0.68% - High Reward Trade
IMTX - Stock Analysis
3447 Comments
1802 Likes
1
Melsa
Expert Member
2 hours ago
Who else is thinking deeper about this?
👍 152
Reply
2
Chisato
Engaged Reader
5 hours ago
Genius and humble, a rare combo. 😏
👍 176
Reply
3
Chatham
Daily Reader
1 day ago
This feels like I should do something but won’t.
👍 57
Reply
4
Lisabella
Influential Reader
1 day ago
Energy like this is truly inspiring!
👍 13
Reply
5
Karlene
Influential Reader
2 days ago
Short-term price swings indicate selective investor activity, highlighting sectors with the strongest performance.
👍 197
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.